Dr. Tashko’s Key Clinical Trials
GLP-1 Medications and Addiction — A New Frontier in Metabolic and Brain Health
GLP-1 medications are known for weight loss and diabetes control, yet emerging data suggests broader effects. Many patients report reduced cravings for alcohol, nicotine, and other behaviors. A large 2026 study highlights a meaningful connection between metabolism and the brain’s reward system. This evolving perspective offers a more integrated understanding of how these therapies influence both physiology and behavior.
Published
Oral PCSK9 Inhibition Reaches a New Milestone With Enlicitide
Oral PCSK9 inhibition represents a major advance in cholesterol care. This new study shows that enlicitide delivers deep and durable LDL reductions without injections. By combining strong biologic effect with daily oral dosing, enlicitide expands personalized options for patients with ASCVD or high cardiovascular risk who remain above LDL targets despite standard therapy.
Published
Olezarsen and Severe Triglycerides: A New Way to Reduce Pancreatitis Risk
Severe hypertriglyceridemia carries a real risk of acute pancreatitis. New research shows that olezarsen, a targeted apoC-III inhibitor, can dramatically lower triglycerides and reduce pancreatitis events. This article explains the biology behind triglyceride driven pancreatitis and how this new therapy changes prevention strategies for high risk patients.
Published
How Oats Lower Cholesterol Through the Gut Microbiome
This recent randomized study shows that oats lower cholesterol through more than fiber alone. Gut microbes transform oat phenolic compounds into active metabolites that directly influence LDL cholesterol. The findings explain why oat responses vary between individuals and why dose and dietary context matter. This research reframes oats as a microbiome active food with meaningful metabolic impact.
Published
RSV Vaccination in Older Adults: What New Evidence Means for Care
Respiratory syncytial virus causes serious illness and hospitalization in older adults. New randomized data now show that RSV vaccination significantly reduces RSV related hospitalizations and severe respiratory outcomes. This article explains how RSV vaccines work, who benefits most, and how new evidence may change current clinical practice for adults aged 60 and older.
Published
Categorized as Dr. Tashko’s Key Clinical Trials, Hospital, Insights from Dr. Tashko, Mortality, Vaccine
Fish Oil and Heart Risk in Hemodialysis Patients
Omega 3 fatty acids are essential nutrients with powerful anti-inflammatory effects. A major NEJM trial now shows that fish-oil supplementation significantly reduces cardiovascular events in patients receiving hemodialysis. This patient-focused summary explains how omega 3 works, why dialysis patients face extreme heart risk, and how targeted supplementation may offer meaningful protection when few therapies exist.
Published
Evolocumab for Heart Risk Before a First Heart Attack or Stroke
PCSK9 inhibitors represent a major advance in cholesterol management. The VESALIUS-CV trial shows that evolocumab reduces first cardiovascular events in patients with atherosclerosis or diabetes, even without a prior heart attack or stroke. These findings expand prevention strategies beyond traditional secondary prevention and support earlier, more personalized lipid lowering approaches.
Published
Why the FDA Approved Mounjaro for Children Age 10+ with Type 2 Diabetes
The FDA approval of Mounjaro for children age 10 and older reflects a major shift in pediatric type 2 diabetes care. New evidence shows meaningful A1c reduction and weight improvement in youth, addressing insulin resistance and appetite biology together. This article explains why the FDA approved tirzepatide, what the studies showed, and how this decision fits into modern metabolic care.
Published
Cardiovascular Outcomes With Tirzepatide in Type 2 Diabetes
Tirzepatide delivers powerful glucose and weight reduction, but cardiovascular safety remains essential. The SURPASS-CVOT trial compared tirzepatide with dulaglutide in patients with established heart disease. This article explains what noninferiority truly means, why active-comparator trials matter, and how these findings fit into modern cardiometabolic care.
Published
Categorized as Diabetes Care, Dr. Tashko’s Key Clinical Trials, Heart Health, Insights from Dr. Tashko
High-Dose Influenza Vaccine and Hospitalization Risk in Older Adults
High-dose influenza vaccination may reduce hospitalizations in adults over 65. A large New England Journal of Medicine trial found fewer admissions for influenza and pneumonia compared with standard-dose vaccination. While absolute risks remain low, the relative reduction in severe outcomes carries meaningful implications for older adults with chronic conditions and winter vulnerability.
Published
Semaglutide 7.2 mg: Stronger Results for Obesity With and Without Diabetes
Semaglutide 7.2 mg produced greater weight loss and a larger HbA1c reduction than the current 2.4 mg dose in adults with and without type 2 diabetes. Participants more often reached substantial weight-loss milestones, including 15%, 20%, and 25%, alongside stronger waist and metabolic improvements. The safety profile remained consistent and manageable, underscoring a meaningful new option for patients who need higher-level support.
Published
Oral PCSK9 Therapy for Familial High Cholesterol and Beyond
Familial hypercholesterolemia raises LDL from birth and increases long term cardiovascular risk. Many patients use strong statins and ezetimibe yet still miss LDL goals. The new oral PCSK9 inhibitor enlicitide changes this landscape. In the CORALreef trial, this daily pill cut LDL by nearly 60 percent and matched placebo for safety. The format supports consistent long term use.
Published